# Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine

> **NCT03303092** · PHASE2,PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 357 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** TEV-48125
- **DRUG:** TEV-48125 or placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03303092
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-19
- **Primary completion:** 2019-11-22
- **Final completion:** 2019-11-22
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2021-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03303092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03303092, "Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03303092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*